Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Fig. 2

Statistical analysis of PFS in subgroups defined by a HER2 mRNA expression (≤median vs. >median), b PIK3CA status (mutated vs. non-mutated), and c PIK3CA status in combination with HER2 mRNA expression. See Additional file 1: Tables S2 and S3 for a table of PFS values and hazard ratios. CI confidence interval, HER human epidermal growth factor receptor, HR unstratified hazard ratio, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us